polski | english | login
Array|Array|Array|Array|Array|Array

DOI: 10.18544/PEDM-22.04.0065
Pediatr Endocrinol Diabetes Metab 2016;22,4:163-169

Musculoskeletal/Radiological Manifestations of Mucolipidosis II (I-Cell disease) in late Adolescence/Early Adulthood

Ali Gholamrezanezhad, Dayna Weinert, Christos Kosmas, Peter Young, Mark Robbin

Key words

Mucolipidosis II, I-Cell disease, Bone, X Ray, Musculoskeletal

Abstract

Mucolipidosis type II (I-Cell disease) is a rare autosomal recessive lysosomal disorder, resulting from functional deficiency of lysosomal enzymes due to an impaired targeting of the enzymes to lysosomes, which leads to an abnormal cell architecture and the overflow of lysosomal enzymes into the body fluids. The life expectancy of the patients is poor, with multisystem deterioration leading to death in early childhood. According to the available reports, patients with I-cell disease do not survive beyond the first decade of life. Here, we describe and illustrate various radiological-musculoskeletal manifestations of a rare case of mucolipidosis II who has been a survivor up to now, 20 years old. The course of her disease has been complicated by early severe visual compromise due to optic nerve swelling, hearing loss and mitral valve regurgitation/stenosis, bilateral carpal tunnel, and severe growth impairment. Our case demonstrates several skeletal features of dysostosis multiplex. At the age of 20, she is wheelchair bound and her medical course is complicated by recurrent pneumonia, treated with multiple hospitalizations, antibiotics, and BiPAP. She is on outpatient palliative care, Do Not Resuscitate/Do Not Intubate (DNR/DNI) status.

Introduction

The mucolipidoses are a heterogeneous group of inherited metabolic disorders caused by enzyme deficiencies that lead to progressively debilitating disorders affecting many body organs. Mucolipidosis II, also known as Inclusion Cell or I-Cell disease, is an autosomal recessive lysosomal disorder, resulting from the deficiency of the heterohexameric lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase enzyme caused by mutations in the GNPTAB gene. An impaired phosphotransferase activity inhibits the synthesis of the critical lysosomal trafficking marker mannose 6-phosphate on to lysosomal hydrolases and other glycoproteins [1, 2], which results in a functional deficiency of lysosomal enzymes and a progressive development of abnormal cell architecture, vacuolated lymphocytes and unusual intracytoplasmic inclusion bodies in cells of mesenchymal origin, especially fibroblasts (I-cells). On the other hand, targeting of lysosomal enzymes to lysosomes is impaired, leading to the overflow of lysosomal enzymes into the serum, spinal fluid, and urine [3].

The life expectancy of the patients is poor, with multisystem deterioration leading to death in early childhood. According to the available reports, patients with I-cell disease do not survive beyond the first decade of life [4]. Here we report radiographic musculoskeletal findings of a rare case of I-cell disease, who has been a survivor up to now, 20 years old.

 

Case report

Our patient was born as a full term pregnancy complicated by pre-eclampsia. According to her parents she was first noted to have an abnormal grasp of her bottle and a trigger finger. Genetic and metabolic testing led to the diagnosis of the I cell disease. She walked at one year of age and cognitive and language development was normal. She subsequently developed severe visual compromise due to optic nerve swelling, hearing loss and mitral valve regurgitation/stenosis. At five years of age, she had bilateral carpal tunnel surgery.

At the age of 9 years, the patient presented to our hospital with bilateral hip pain. On physical examination, her height was below the 5th percentile at 82cm. She had coarse facial features typical for mucolipidosis and a protuberant abdomen due to marked hepatomegaly. She walked somewhat hunched over with a wide-based waddling gait on supinated feet. Proximal muscle weakness and restricted range of motion of the joints of all extremities were also noted. Radiographs showed dystrophic changes of the hips (Fig. 1).

At the age of 12, she presented with new onset headaches. Her mobility was limited and she complained of weakness and back and hip pain. Growth was arrested at a height of 85.8 cm. Cognitive and neurologic examination remained normal. Increase in hip flexion contractures to 40 degrees and compensatory increase in lumbar lordosis resulted in her being able to walk only a few steps in a pitched forward position. Elbow and knee contractures as well as short and broad fingers were also noted. Radiographs confirmed the musculoskeletal changes (Fig. 2) Head CT was normal and headaches were attributed to migraine. MRI of the spine showed mild anterolisthesis of C1 on C2, mild posterior effacement of the thecal sac and minimal effacement of the cord posteriorly (not shown). The thoracolumbar spine showed findings consistent with her storage disease without cord compression (Fig. 3).

Between the ages of 15 and 16, her pain continued to worsen and she ceased to ambulate. Her height decreased to 78.8cm. She developed flexion contractures at the waist and knees, decreased range of motion of elbows and fingers and clawing of the hands. Her weakness on physical exam became more profound, her lower extremities became hyper-reflexic and her feet pronated. Kyphosis of the thoracolumbar spine worsened.

At the age of 20 she is wheelchair-bound and her medical course is complicated by recurrent pneumonia, treated with multiple hospitalizations, antibiotics, and BiPAP. Her recent abdominal ultrasound shows focal fatty infiltration of the liver as well as cholelithiasis with no evidence of cholecystitis. She is on outpatient palliative care, Do Not Resuscitate/Do Not Intubate (DNR/DNI) status.


Discussion

Storage diseases encompass a large group of more than 100 rare inherited metabolic disorders, including mucolipidoses, mucopolysaccharidoses and sphingolipidoses, which show certain similarities, but also significant differences in their phenotypic and clinical picture. This partly depends on the specific tissue or organs most affected and the type of abnormal substrate that accumulates [4–10]. For example, the visceral storage of patients with mucolipidoses may consist of both mucopolysaccharides and glycolipids, while it consists of mucopolysaccharides in patients with mucopolysaccharidoses and glycolipids in those with sphingolipidoses. However, unlike mucopolysaccharidoses, mucopolysacchariduria is not seen in patients with mucolipidoses. Phenotypically, although dysostosis multiplex is not a feature of sphingolipidoses, it is common in both mucolipidoses and mucopolysaccharidoses [11]. As the biochemical and clinical features of these storage diseases are overlapping, one can expect overlapping radiological features as well [12,13]. More specifically, the radiographic findings of mucolipidoses have significant overlap and similarity to those observed in mucopolysaccharidoses, a condition with which I-cell disease may be easily confused [11].

Mucolipidoses are a spectrum of diseases with significant overlap between underlying pathogenesis and molecular mechanisms as well as clinical manifestations. There are eight distinct mucolipidoses, including Gangliosidosis I, Gangliosidosis II, Fucosidosis, Mannosidosis, Juvenile Sulfatidosis (Austin type), Mucolipidosis I (Lipomucopolysaccharidosis), Mucolipidosis II (I Cell disease), and Mucolipidosis III (Pseudopolydystrophy) [11]. Unfortunately, due to the severity of the progression of the I cell disease, the affected patients typically do not survive past the first decade and pass away within the first 5-6 years of life [4]. To the best of our knowledge, this is the first report in the literature of the I-Cell disease of the casewho has been a survivor up to the late second decade of life. Our report has the potential to improve our understanding of a natural course of the skeletal abnormalities associated with mucolipidoses and can help investigators and clinicians to develop musculoskeletal-specific therapies.

As confirmed by our case, the developmental delay and progressive psychomotor deterioration are common presentations of metabolic storage diseases [3, 11]. Growth is severely impaired [11], as our case suffered from the arrest of height and weight gain since her first decade of life. A Progressive ambulation decline is also an important clinical feature. The I Cell disease most severely affects the skeletal system, in which trabeculation of osseous and cartilaginous structures are abnormal. Craniofacial and orthopedic manifestations can be evident at birth, but become more obvious within the first year [1], and mainly include dysostossis multiplex, but also facial dysmorphism, kyphosis, clubfeet, deformed long bones, and/or the dislocation of the hips [4]. Herman and McAlister also reported radiographic skeletal features of I-Cell disease in neonates [7]. They described it as a transient osteopathy resembling rickets and hyperparathyroidism with butterfly vertebral body and dysharmonic epiphyseal ossification. The diagnosis is sometimes missed or delayed, especially in those with more attenuated forms of disease, as it may present with rickets-like picture [5]. In fact, the major challenge for radiologists is the overlap of radiological and musculoskeletal features of storage diseases. For example, almost all types of mucopolysaccharidoses show dysostosis multiplex. However, the severity of the musculoskeletal involvement can be milder in type III (Sanfilippo syndrome), but often more severe in type IV (Morquio syndrome) [9].

Our case shows that dysostosis multiplex is the main imaging feature of the disease. Dysostosis multiplex, previously known as Gargoylism [12], is the name proposed to describe a syndrome of progressive skeletal dysplasia and constellation of radiographic changes characteristically seen in different metabolic disorders, including storage diseases. The syndrome is caused by the lack of skeletal remodeling, resulting in ossification abnormalities, as well as cartilaginous, ligamentous, and tendinous abnormalities due to deposition of abnormally metabolized substances. As shown by our case, dysostosis multiplex can be considered the main musculoskeletal feature of the I-Cell disease [9, 13, 14]. Radiographic features of dysostosis multiplex include clavicular abnormalities (Fig. 4), oar-shaped ribs (Ribs that widen at or adjacent to the costochondral junctions and are narrower than typical in the dorsal juxtavertebral arches, Fig. 4) [15], gibbus deformity of thoracolumbar spine [9], which is caused by vertebral body wedge deformity or hypoplasia, flaring of the iliac wings (Fig. 1), hip dysplasia and coxa valga (Fig. 1), abnormal development of phalanges and metacarpals (Fig. 3), thickening of the diaphyseal regions of long bones (Fig. 3), and metaphyseal cupping and fraying, resembling rickets [9]. Previously described malformation and deformity of tubular bones (including disproportion of width and length of the tubular bones due to periosteal new-bone formation leading to cloaking of the long bone, diaphyseal widening and expansion with shortened and undermodeled diaphyses, and epiphyseal dysplasia and submetaphyseal overconstriction of the tubular bones), coarse bony trabeculation, hypoplastic/dysplastic capital femoral epiphyses, delayed epiphyseal ossification, vertebral body deformity with concave anterior, superior, or inferior borders and kyphosis, pelvic dysplasia with narrow basilar portions of the ilia and relatively long pubic and ischial bones, slanting acetabular roofs, coxa valga, and clubfoot deformity have been reported as characteristic musculoskeletal features of the disease [15–17], are consistent with radiological findings of our case. Restricted range of motion in all peripheral joints, contractures, and generalized hypotonia are also another main musculoskeletal presentation of the I-cell disease.

As shown by our case, the respiratory insufficiency and recurrent pulmonary infections are one of the major morbidities of these patients and have been reported as the main cause of their mortality [15]. This can be partly explained by obstructive oropharyngeal and upper airway disease (e.g. caused by macroglossia) and partly due to severe kyphosis and gradual stiffening of the thoracic cage. Our case had evidences of pulmonary infiltrates and fibrosis, which can be indicative of sequela of recurrent infections.

The basis for the musculoskeletal abnormalities characteristic of the mucolipidoses is not fully understood. However, as many of patients with storage diseases need orthopedic attention for perceived musculoskeletal discomfort, musculoskeletal and pediatric radiologists should be aware of their radiographic manifestations. Our case shows that some of these musculoskeletal abnormalities become more conspicuous with time (Fig. 1) and cause significant morbidity. Radiological studies reveal the arrest of osseous maturation from the end of first decade to late adolescence/early adulthood.


Acknowledgement 

Dr Mark Robbin, the senior author of this publication and professor of radiology, passed away peacefully in Cleveland, Ohio, on January 21, 2017 (few months after the initial submission of this manuscript), after a long battle with renal cancer. He was program director of diagnostic radiology residency and musculoskeletal imaging fellowship and served as the vice chairman of education at the Department of Radiology, University Hospitals of Cleveland, Case Western Reserve University. He was a physician, radiologist, teacher, scholar, author, researcher, and athlete. God bless him.


Reference

1. Cathey SS1, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M et al. Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet. 2010; 47(1): 38-48.

2. Dierks T1, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease – Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta. 2009; 1793(4): 710-25.

3. Otomo T, Muramatsu T, Yorifuji T, Okuyama T, Nakabayashi H, Fukao T et al. Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. J Hum Genet. 2009; 54(3): 145-51.

4. Mahfouz AK, George G, Al-Bahlani SS, Al Nabhani MZ. Difficult intubation management in a child with I-cell disease. Saudi J Anaesth. 2010; 4 (2): 105-7.

5. Leroy JG, Cathey SS, Friez MJ. Mucolipidosis III Alpha/Beta. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993-2014. 2008 Aug 26 [updated 2012 May 10].

6. Lin MH1, Pitukcheewanont P. Mucolipidosis type II (I-cell disease) masquerading as rickets: two case reports and review of literature. J Pediatr Endocrinol Metab. 2012; 25 (1-2): 191-5.

7. Owada M. I-cell disease and pseudo-Hurler polydystrophy. Nihon Rinsho. 1995; 53(12): 3028-34.

8. Herman TE1, McAlister WH. Neonatal mucolipidosis II (I-cell disease) with dysharmonic epiphyseal ossification and butterfly vertebral body. J Perinatol. 1996; 16(5): 400-2.

9. Morishita K and Petty R. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology. (2011) 50 (suppl 5): v19-v25.

10. Xing M, Parker EI, Moreno-De-Luca A, Harmouche E, Terk MR. Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders. Br J Radiol 2014; 87: 20130467.

11. Spranger JW and Wiedemann HR. The genetic mucolipidoses. Dianosis and differential diagnosis. Humangenetik.1970; 9: 113-139.

12. Smith EB, Hempelmann TC, Moore S, Barr DP. Gargoylism (dysostosis multiplex): two adult cases with one autopsy. Annals of Internal Medicine. 1952; 36(2:2): 652-67.

13. Stevenson DA and Steiner RD. Skeletal abnormalities in lysosomal storage diseases. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:406-16.

14. Leroy JG, Cathey S, Friez MJ. Mucolipidosis II. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 2008 Aug 26 [updated 2012 May 10].

15. Spranger JW, Brill PW, Poznanski A. Bone Dysplasias: Atlas of Genetic Disorders of Skeletal Development. 2 ed. New York, NY: Oxford University Press; 2002:295-9.

16. Pazzaglia UE, Beluffi G, Campbell JB, Bianchi E, Colavita N, Diard F, Gugliantini P, Hirche U, Kozlowski K, Marchi A, Nayanar V, Pagani G. Mucolipidosis II: correlation between radiological features and histopathology of the bones. Pediatr Radiol 1989; 19: 406-413. 

17. Melo MD, Obeid G. Radiolucent lesions of the maxillofacial complex in a patient with mucolipidosis type II (MLSII): case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: e30-e33.

advanced search »

Article in databases

DOI: 10.18544/PEDM-22.04.0065
PUBMED: view

Similar articles

...

Risk factors for cardiovascular disease in children with type 1 diabetes ...

The Pro12Ala PPARg2 gene polymorphism involves residual C-peptide secret ...

Response to low dose indomethacin in two children with nephrogenic diabe ...

Suspicion of anorexia nervosa as a cause of delayed diagnosis of brain t ...

Pediatric Endocrinology Diabetes and Metabolism

2018; 24, 1: 1-51
2017; 23, 4: 169-222
2017; 23, 3: 117-168
2017; 23, 2: 59-116
2017; 23, 1: 1-58
2016; 22, 4: 133-180
2016; 22, 3: 81-132
2016; 22, 2: 43-79
2016; 22, 1: 1-42
2015; 21, 4: 149-191
2015; 21, 3: 97-148
2015; 21, 2: 51-96
2015; 21, 1: 1-50
2014; 20, 4: 131-182
2014; 20, 3: 83-130
2014; 20, 2: 35-82